基于银病现实世界的证据的药物分层:叙述性审查
William Göte Sindrup1, Alex Birk Nielsen1, Amanda Kvist-Hansen1,2
1Department of Dermatology and Allergy, Copenhagen University Hospital-Herlev and Gentofte, Gentofte Hospitalsvej 15, Hellerup, 2900, Copenhagen, Denmark.
Dermatology and therapy
|December 10, 2025
概括
牛皮的生物治疗方法已经进步,但个性化治疗选择仍然具有挑战性. 未来的策略可能会整合遗传学和临床数据,以获得更好的结果和更少的副作用.
科学领域:
- 皮肤病学和免疫学
- 药物基因组学 药物基因组学
- 个性化医疗是个性化的医疗.
背景情况:
- 在过去20年中,对中度至重度牛皮的生物疗法取得了重大进展.
- 治疗目标已经从50%增加到90%的牛皮区域和严重性指数 (PASI) 减少.
- 随机对照试验 (RCT) 的局限性包括患者子集选择,持续时间短,缺乏比较数据.
研究的目的:
- 为了解决缺乏关于启动和选择牛皮最佳生物治疗的最终指南的问题.
- 探索围绕最佳治疗是否能降低并发症风险的不确定性.
- 确定影响治疗反应的因素和现实世界牛皮管理中的不良事件.
主要方法:
- 对临床试验数据和关于生物牛皮治疗的现实世界证据的审查.
- 分析与特定生物药物相关的不良事件 (例如TNF抑制剂,IL-17抑制剂,IL-12/23抑制剂).
- 研究患者特异性因素 (BMI,吸烟,年龄,先前治疗) 和预测标记 (HLA-C*06:02,初始反应,药物水平).
主要成果:
- 患者对生物制剂的反应不同,包括不反应和有效性丧失.
- 确定的不良影响:肺结核的重新激活 (TNF抑制剂),炎症性肠病恶化 (IL-17抑制剂),心血管事件 (IL-12/23抑制剂).
- 与高BMI,吸烟,年龄较大和先前的生物使用相关的较差结果;遗传标记和药物水平的预测价值建议.
结论:
- 目前的生物疗法具有很高的疗效,但缺乏个性化的选择指南.
- 现实世界的数据突出显示了与非最佳治疗结果相关的重大不良事件和因素.
- 遗传标记,临床数据和技术的整合对于未来个性化的牛皮治疗策略至关重要.
相关概念视频
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
380
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
380
01:19Clinical Applications of Epidermal Stem Cells
3.2K
Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
3.2K
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
4.0K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
4.0K
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
134
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
134
01:26Atherosclerosis III: Management
293
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
293
01:12Analysis of Population Pharmacokinetic Data
653
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
653